MAFA
SRPT icon

MJT & Associates Financial Advisory’s Sarepta Therapeutics SRPT Stock Holding History

MJT & Associates Financial Advisory’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.26K Hold
69
– – ﹤0.01% 393
2026
Q2 		$1.24K Hold
69
– – ﹤0.01% 410
2026
Q1 		$1.5K Hold
69
– – ﹤0.01% 390
2025
Q4 		$1.49K Buy
+69
New +$1.45K ﹤0.01% 400

Other funds holding SRPT

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

MJT & Associates Financial Advisory's SRPT Position: Q3 2026 in Review

MJT & Associates Financial Advisory held its Sarepta Therapeutics (SRPT) position steady in Q3 2026 at 69 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #393.

MJT & Associates Financial Advisory first reported a position in SRPT in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.5K in Q1 2026. 9 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • MJT & Associates Financial Advisory held 69 shares of Sarepta Therapeutics worth $1.26K as of Q3 2026.
  • MJT & Associates Financial Advisory left its Sarepta Therapeutics share count unchanged in Q3 2026.
  • Sarepta Therapeutics made up ﹤0.01% of MJT & Associates Financial Advisory's portfolio in Q3 2026, its #393 holding.
  • MJT & Associates Financial Advisory first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • MJT & Associates Financial Advisory's Sarepta Therapeutics position peaked at $1.5K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on MJT & Associates Financial Advisory's 13F filing for Q3 2026, filed 7 Oct 2026.